PROTAC-DB 2.0: an updated database of PROTACs
Nucleic Acids Research · 06.01.2023 · 51 (D1) · D1367-D1372
DOI: 10.1093/nar/gkac946 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 27.10.2022. Verfasst von Gaoqi Weng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzho…. Hauptthemen laut MEDLINE: Proteasome Endopeptidase Complex, Proteolysis, Databases, Protein. Die Arbeit wurde bisher 145-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Proteolysis targeting chimeras (PROTACs), which harness the ubiquitin-proteasome system to selectively induce targeted protein degradation, represent an emerging therapeutic technology with the potential to modulate traditional undruggable targets. Over the past few years, this technology has moved from academia to industry and more than 10 PROTACs have been advanced into clinical trials. However, designing potent PROTACs with desirable drug-like properties still remains a great challenge. Here, we report an updated online database, PROTAC-DB 2.0, which is a repository of structural and experimental data about PROTACs. In this 2nd release, we expanded the number of PROTACs to 3270, which corresponds to a 96% expansion over the first version. Meanwhile, the numbers of warheads (small molecules targeting the proteins of interest), linkers, and E3 ligands (small molecules recruiting E3 ligases) have increased to over 360, 1500 and 80, respectively. In addition, given the importance and the limited number of the crystal target-PROTAC-E3 ternary complex structures, we provide the predicted ternary complex structures for PROTACs with good degradation capability using our PROTAC-Model method. To further facilitate the analysis of PROTAC data, a new filtering strategy based on the E3 ligases is also added. PROTAC-DB 2.0 is available online at http://cadd.zju.edu.cn/protacdb/.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
- CarbonSilicon AI Technology Co., Ltd, Hangzhou 310018, Zhejiang, China.
- Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410004, Hunan, China.
ORCID-Profile: Gaoqi Weng, Dongsheng Cao, Tingjun Hou
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Research and Development Program of China
Zitieren
APA
Weng, G., Cai, X., Cao, D., Du, H., Shen, C., Deng, Y., He, Q., Yang, B., Li, D., & Hou, T. (2023). PROTAC-DB 2.0: an updated database of PROTACs. Nucleic Acids Research, 51(D1), D1367-D1372. https://doi.org/10.1093/nar/gkac946
Vancouver
Weng G, Cai X, Cao D, Du H, Shen C, Deng Y, et al. PROTAC-DB 2.0: an updated database of PROTACs. Nucleic Acids Research. 2023;51(D1):D1367-D1372. doi:10.1093/nar/gkac946
BibTeX
@article{Weng2023,
author = {Weng, Gaoqi and Cai, Xuanyan and Cao, Dongsheng and Du, Hongyan and Shen, Chao and Deng, Yafeng and He, Qiaojun and Yang, Bo and Li, Dan and Hou, Tingjun},
title = {PROTAC-DB 2.0: an updated database of PROTACs},
journal = {Nucleic Acids Research},
year = {2023},
volume = {51},
number = {D1},
pages = {D1367--D1372},
doi = {10.1093/nar/gkac946}
}
EUVIMED